Tuesday, February 9, 2016

NY buyout firm adds BioClinica, CoreLabs

$7.25 a share, a five-year high for BioClinica

NY buyout firm adds BioClinica, CoreLabs


JLL Partners, New York, says it has agreed to buy publicly-traded BioClinica, Newtown Square, for $123 million, or $7.25 a share. JLL plans to merge the medical-therapy clinical-testing firm with CoreLab Partners Inc., Princeton, which develops "medical imaging solutions and cardiac safety devices." BioClinica boss Mark L. Weinstein was named to lead the combined firms.

The per-share sale price represents a five-year high for BioClinica, which has been public since the early 1990s, but is still below its 2007 high of nearly $10 a share. Major owners include Princeton-based Covance, with around 2.4 million shares, and Wellington Management Co., with 1.5 million.

BioClinica employs around 530. CoreLab employs around 325. The impact of the combination on both companies' spending and employment is "to be determined," Morgan Dub Karpo, spokeswoman for the buyer, told me.

JLL managing director Dan Agroskin said his firm "will conservatively capitalize the combined business and look forward to supporting its continued growth."

CoreLab's controlling owner, Ampersand Capital Partners, will keep a stake in the combined company.

We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog

PhillyDeals posts interviews, drafts and updates that Joseph N. DiStefano writes alongside his Sunday and Monday columns and ongoing articles about Philadelphia-area business.

DiStefano studied economics, history and a little engineering at Penn. He taught writing and research at St. Joe’s. He has written for the Inquirer since 1989, except when he left a few times to work at Bloomberg and elsewhere. He wrote the book Comcasted, and raised six kids with his wife, who is a saint.

Reach Joseph N. at JoeD@phillynews.com, 215.854.5194, @PhillyJoeD. Read his blog posts at http://www.philly.com/PhillyDeals and his Inquirer columns at http://www.philly.com/philly/columnists/joseph-distefano/. Bloomberg posts his items at NH BLG_PHILLYDEAL.

Reach Joseph N. at JoeD@phillynews.com or 215 854 5194.

Joseph N. DiStefano
Also on Philly.com:
letter icon Newsletter